
AnnJi Pharmaceutical Launches Phase 3 Trial for Kennedy's Disease
AnnJi Pharmaceutical has initiated the U.S. site activation for its pivotal Phase 3 ROMA-KD study, marking a critical step in testing AJ201 as the first potential treatment for spinal and bulbar muscular atrophy. The oral small molecule aims to address the underlying causes of this progressive neuromuscular disorder.
























